IP Library Granted Patent US 9,056,151
Granted Patent B2
US 9,056,151 · App. 11/673,972 · Granted Jun 16, 2015

Methods for collagen processing and products using processed collagen

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,056,151
App. No.
11/673,972
Granted
Jun 16, 2015
Kind
B2
Abstract

Purifying human derived collagen from human tissue includes treating harvested human tissue with an enzyme to form a collagen product, deactivating the enzyme with a non-alkaline enzyme deactivation solution, and collecting the collagen product resulting from the enzyme treatment, where the collected collagen product includes a preserved amount of its natural collagen constituents. Various medical implants can be formed using the isolated, enzymatically-treated human derived collagen having an amount of its natural collagen constituents preserved, and may include implantable sponges, patches, tubes, structural supports and coatings, and which may be used for repair, barrier, support and/or stabilization purposes.

Claims (21)

1. A medical implant comprising isolated, enzymatically-treated human derived collagen having a preserved amount of its natural collagen constituents, wherein the enzyme treatment comprises digesting the collagen with ficin and deactivating the ficin with a non-alkaline sodium chlorite solution to maintain growth factors and morphogenic proteins otherwise stripped away by exposure to an alkaline solution, wherein the collagen is lyophilized by exposing the collagen to a vapor phase cross-linking agent, the cross-linking agent comprising at least one of acetaldehyde, dialdehyde starch, glycerol polyglycidyl ethers, polyethylene glycol diglycidyl ethers, polyvalent metallic oxides, or a combination thereof, wherein the collagen comprises cartilage fragments, a plasticizer and angiogenesis promoting factors, the angiogenesis promoting factors comprising SEMA3.

2. The medical implant of claim 1 , wherein the collagen is fibrillar human derived collagen.

3. The medical implant of claim 1 , wherein the collagen is particulate human derived collagen.

4. The medical implant of claim 1 , wherein said implant comprises a wound repair matrix.

5. The medical implant of claim 1 , wherein said implant comprises an absorbent hemostat.

6. The medical implant of claim 1 , wherein said implant comprises a medical repair patch.

7. The medical implant of claim 6 , wherein the medical repair patch is a woven patch.

8. The medical implant of claim 6 , wherein the medical repair patch is a non-woven patch.

9. The medical implant of claim 6 , wherein the medical repair patch is a braided patch.

10. The medical implant of claim 6 , wherein the medical repair patch is a film patch.

11. The medical implant of claim 6 , wherein the medical repair patch is a knitted patch.

12. The medical implant of claim 6 , wherein the medical repair patch is at least two of a woven, a non-woven, a braided, a film, and a knitted patch.

13. The medical implant of claim 1 , wherein said implant comprises a vascular graft.

14. The medical implant of claim 1 , wherein said implant comprises a neural graft.

15. The medical implant of claim 1 , wherein said implant comprises a sphincter repair matrix.

16. The medical implant of claim 1 , wherein said implant comprises a film.

17. The medical implant of claim 1 , wherein said implant comprises a prosthetic having a coating of the enzymatically-treated human derived collagen.

18. The medical implant of claim 1 , wherein said implant comprises an implantable instrument having a coating of the enzymatically-treated human derived collagen.

19. The medical implant of claim 1 , wherein said implant comprises a structural support sling.

20. The medical implant of claim 1 , wherein said implant comprises a bioactive agent.

21. A medical implant comprising: reconstituted human derived collagen, wherein the human derived collagen comprises a preserved amount of its native collagen constituents of growth factors and morphogenic proteins, wherein the collagen is lyophilized by exposing the collagen to a vapor phase cross-linking agent, the cross-linking agent comprising at least one of acetaldehyde, dialdehyde starch, glycerol polyglycidyl ethers, polyethylene glycol diglycidyl ethers, polyvalent metallic oxides, or a combination thereof, wherein the collagen comprises cartilage fragments, a plasticizer and angiogenesis promoting factors, the angiogenesis promoting factors comprising SEMA3, and the medical implant comprises a cartilage repair structure.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2011
From: OSTEOTECH, INC.
To: WARSAW ORTHOPEDIC, INC.
Reel/Frame 026196/0585 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2007
From: LAURITZEN, NELS J.; SHIMP, LAWRENCE A.
To: OSTEOTECH, INC.
Reel/Frame 019101/0822 →